Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medx Health Corp V.MDX

Alternate Symbol(s):  MDXHF

MedX Health Corp. is a medical device and software company. It develops and manufactures skin-related screening tools and phototherapy devices for pain relief and tissue repair. It focuses on skin health with its SIAscopy on DermSecure telemedicine platform, utilizing its SIAscopy technology. SIAscopy is a medical device technology that is used to scan skin for suspicious moles and lesions and, including DermSecure, its telemedicine software application, and phototherapeutic medical devices, which use light energy in lower-level laser and light-emitting diode to provide treatment of pain and tissue damage in the rehabilitation market. Its products SIAMETRICS, SIMSYS, and MoleMate include hand-held devices that use patented technology utilizing light and its remittance to view up to two millimeters beneath suspicious moles and lesions in a pain free, non-invasive manner. Its SIAscopy on DermSecure telemedicine platform enables the Web-based operation of its SIAscopy scanning technology.


TSXV:MDX - Post by User

Comment by Insightful1on Nov 22, 2021 10:35am
153 Views
Post# 34152651

RE:More News...

RE:More News...MedX stated they were initiating global pilots/trials and it seems we are starting to see the results of this in the news cycle. The release of the Medical Advisory Boards publications should increase MedX's adoption rate as it becomes the de facto standard for teledermatology. I suspect we will continue to see a large number of the pilot/trial announcements. The next confirmation milestone will be as these pilot/trials convert into large scale rollouts. Certainly having the thought leaders in the dermatology space endorse MedX's technology will increase their global acceptance rate. Other posters have said Derms haven't heard about this technology, well that is about to change. So I think we can expect a steady flow of news suggesting the new leadership is deeply focused on results. 
<< Previous
Bullboard Posts
Next >>